Headquarters
United States
Every company in the roster headquartered in United States.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
54 of 54 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 A2 Biotherapeutics Inc.Private | 4 assets: 4 Ph 2 | A2B395Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026A2B530 · Phase 1/2 |
 Avenzo Therapeutics, Inc.Private | 3 assets: 3 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 |
| 3 assets: 2 Ph 3, 1 Ph 1 | PF-08046054Phase 3 · Non-Small Cell Lung Cancer | None on record | |
 HUYABIO International, LLC.Private | 2 assets: 2 Ph 1 | HBI-2376Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026HBI-2376 · Phase 1 |
| 2 assets: 2 Ph 1 | LonitoclaxPhase 1 · Acute Myeloid Leukemia | Dec 2026ZE 50-0134 · Phase 1 | |
 Myeloid TherapeuticsPrivate | 2 assets: 2 Ph 1 | MT-302Phase 1 · Non-Small Cell Lung Cancer | 31 Jan 2027MT-304 · Phase 1 |
 Neonc Technologies, Inc.NTHI · Nasdaq | 2 assets: 1 Ph 2, 1 other | NEO212Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027NEO212 · Phase 1/2 |
 OncoC4, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 1 | GotistobartPhase 3 · Non-Small Cell Lung Cancer | 30 Nov 2026Gotistobart · Phase 1/2 |
 7 Hills Pharma, LLCPrivate | 1 asset: 1 Ph 2 | AlintegimodPhase 1/2 · Non-Small Cell Lung Cancer | 31 Dec 2027Alintegimod · Phase 1/2 |
 Alterome Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | ALTA3263Phase 1 · Non-Small Cell Lung Cancer | May 2029ALTA3263 · Phase 1 |
 Asher Biotherapeutics, Inc.Private | 1 asset: 1 Ph 1 | AB248Phase 1 · Non-Small Cell Lung Cancer | None on record |
Auricula Biosciences Inc.Private | 1 asset: 1 Ph 2 | WEF-001Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2028WEF-001 · Phase 1/2 |
 Calico Life Sciences LLCPrivate | 1 asset: 1 Ph 1 | ABBV-CLS-484Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Clasp Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CLSP-5282Phase 1 · Non-Small Cell Lung Cancer | May 2029CLSP-5282 · Phase 1 |
 Crossbow Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CBX-250Phase 1 · Acute Myeloid Leukemia | Jan 2027CBX-250 · Phase 1 |
| 1 asset: 1 Ph 2 | FMC-376Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2027FMC-376 · Phase 1/2 | |
| 1 asset: 1 Ph 2 | FF-10832Phase 2 · Non-Small Cell Lung Cancer | May 2029FF-10832 · Phase 2 | |
 GluBio Therapeutics Inc.Private | 1 asset: 1 Ph 1 | GLB-001Phase 1 · Acute Myeloid Leukemia | None on record |
 Iambic Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | IAM1363Phase 1 · Non-Small Cell Lung Cancer | Dec 2027IAM1363 · Phase 1 |
 Immunophotonics, Inc.Private | 1 asset: 1 Ph 3 | IP-001Phase 2/3 · Non-Small Cell Lung Cancer | Dec 2033IP-001 · Phase 2/3 |
 Incendia TherapeuticsPrivate | 1 asset: 1 Ph 1 | PRTH-101Phase 1 · Non-Small Cell Lung Cancer | None on record |
 InduPro, Inc.Private | 1 asset: 1 Ph 2 | IDP-001Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2028IDP-001 · Phase 1/2 |
 Integro TheranosticsPrivate | 1 asset: 1 Ph 2 | LS301-ITPhase 2 · Non-Small Cell Lung Cancer | None on record |
 KaliVir ImmunotherapeuticsPrivate | 1 asset: 1 Ph 1 | VET3-TGIPhase 1 · Non-Small Cell Lung Cancer | 30 Sep 2027VET3-TGI · Phase 1 |
 Keystone Nano, IncPrivate | 1 asset: 1 Ph 1 | Ceramide NanoLiposome (Ceraxa)Phase 1 · Acute Myeloid Leukemia | None on record |
 Kiromic BioPharma Inc.KRBPQ · OTC Pink | 1 asset: 1 Ph 1 | KB-GDT-01Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Kivu Bioscience Inc.Private | 1 asset: 1 Ph 1 | KIVU-107Phase 1 · Non-Small Cell Lung Cancer | 31 Mar 2028KIVU-107 · Phase 1 |
 Linnaeus Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | LNS8801Phase 2/3 · Non-Small Cell Lung Cancer | Feb 2029LNS8801 · Phase 2/3 |
 Marengo Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | STAR0602Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027STAR0602 · Phase 1/2 |
 Memgen, Inc.Private | 1 asset: 1 Ph 1 | MEM-288Phase 1 · Non-Small Cell Lung Cancer | Feb 2027MEM-288 · Phase 1 |
 Newave Pharmaceutical IncPrivate | 1 asset: 1 Ph 1 | LP-118Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026LP-118 · Phase 1 |
 Nimbus Saturn, Inc.Private | 1 asset: 1 Ph 2 | NDI-101150Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Normunity AccelCo, Inc.Private | 1 asset: 1 Ph 1 | NRM-823Phase 1 · Non-Small Cell Lung Cancer | 30 May 2027NRM-823 · Phase 1 |
| 1 asset: 1 Ph 1 | XS-04Phase 1 · Acute Myeloid Leukemia | None on record | |
 Obsidian Therapeutics, Inc.OBX · Nasdaq | 1 asset: 1 Ph 2 | OBX-115Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2029OBX-115 · Phase 1/2 |
 Onchilles Pharma IncPrivate | 1 asset: 1 Ph 2 | N17350Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028N17350 · Phase 1/2 |
 PAQ Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | PT0511Phase 1 · Non-Small Cell Lung Cancer | 18 Oct 2028PT0511 · Phase 1 |
 Partner Therapeutics, Inc.Private | 1 asset: 1 approved | Approved assets only | 31 Dec 2026Zenocutuzumab · Phase 2 |
 Phanes TherapeuticsPrivate | 1 asset: 1 Ph 2 | PT199Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027PT199 · Phase 1/2 |
 Plexium, Inc.Private | 1 asset: 1 Ph 1 | PLX-61639Phase 1 · Non-Small Cell Lung Cancer | Dec 2029PLX-61639 · Phase 1 |
Rgene CorporationPrivate | 1 asset: 1 Ph 2 | BLEX 404Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027BLEX 404 · Phase 2 |
 Rondo TherapeuticsPrivate | 1 asset: 1 Ph 1 | RNDO-564Phase 1 · Non-Small Cell Lung Cancer | 28 Feb 2029RNDO-564 · Phase 1 |
 Salubris Biotherapeutics IncPrivate | 1 asset: 1 Ph 2 | JK08Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Second Life TherapeuticsPrivate | 1 asset: 1 Ph 2 | SL-28Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2027SL-28 · Phase 1/2 |
 Simcha IL-18, Inc.Private | 1 asset: 1 Ph 2 | ST-067Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Solu Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | STX-0712Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026STX-0712 · Phase 1 |
 SynthekinePrivate | 1 asset: 1 Ph 2 | STK-012Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2029STK-012 · Phase 1/2 |
 Teligene USPrivate | 1 asset: 1 Ph 2 | SutetinibPhase 2 · Non-Small Cell Lung Cancer | Dec 2027Sutetinib · Phase 2 |
 VM Oncology, LLCPrivate | 1 asset: 1 Ph 2 | VMD-928Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027VMD-928 · Phase 1/2 |
 Vivace Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | VT3989Phase 1/2 · Non-Small Cell Lung Cancer | 2 Nov 2029VT3989 · Phase 1/2 |
 Volastra Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | VLS-1488Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Vyriad, Inc.Private | 1 asset: 1 Ph 2 | VSV-IFNβ-NISPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
 XYone Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | XYA02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Sep 2029XYA02 · Phase 1/2 |
 Zumutor Biologics Inc.Private | 1 asset: 1 Ph 1 | ZM008Phase 1 · Non-Small Cell Lung Cancer | Dec 2026ZM008 · Phase 1 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).